Status:
COMPLETED
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Lead Sponsor:
Seagen Inc.
Conditions:
Acute Lymphoid Leukemia
Acute Myeloid Leukemia
Eligibility:
All Genders
6+ years
Phase:
PHASE2
Brief Summary
This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.
Eligibility Criteria
Inclusion
- Histologically-confirmed by central review CD30-positive nonlymphomatous malignancy
- Have failed, refused, or have been deemed ineligible for standard therapy
- Measurable disease
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 or a Karnofsky or Lansky Performance Status score greater than or equal to 70
Exclusion
- Primary diagnosis of lymphoma or central nervous system (CNS) malignancy
- History of another primary invasive malignancy that has not been definitively treated or in remission for at least 3 years
- Evidence of active cerebral/meningeal disease
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT01461538
Start Date
October 1 2011
End Date
December 1 2014
Last Update
March 4 2016
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294-3300
2
City of Hope
Duarte, California, United States, 91010-3000
3
PMK Medical Group Inc., DBA Ventura County Hematology Oncology Specialists
Oxnard, California, United States, 93030
4
Rocky Mountain Cancer Centers - Aurora
Aurora, Colorado, United States, 80012